Skip to main content

Advertisement

Table 1 Patients and provider characteristics

From: Impact of 5-HT3 receptor antagonists on chemotherapy-induced nausea and vomiting: a retrospective cohort study

  Breast cancer Carboplatin-treated lung cancer Cisplatin-treated lung cancer
  All Older 5-HT3RAs Palonosetron P All Older 5-HT3RAs Palonosetron P All Older 5-HT3RAs Palonosetron P
N 3,606 1,742 1,864   4,497 2,691 1,806   1,154 764 390  
Age mean (SD) 53.7 (9.8) 53.7 (9.7) 53.7 (10.0) NS 64.9 (10.2) 64.77 (10.2) 65.03 (10.3) NS 60.5 (9.8) 60.1 (9.8) 61.3 (9.8) 0.0476
CCI mean (SD) 0.5 (1.0) 0.5 (1.1) 0.5 (1.0) NS 6.8 (3.2) 6.87 (3.2) 6.71 (3.2) NS 6.5 (3.3) 6.6 (3.3) 6.3 (3.2) NS
Female, N (%) - - - - 2,080 (46.3) 1,258 (46.8) 822 (45.5) NS 459 (39.8) 329 (43.1) 130 (33.3) 0.0014
Year of 5-HT 3 RA initiated     <0.0001     <0.0001     NS
2005 1,428 (39.6) 753 (43.3) 675 (36.2)   1,562 (34.7) 990 (36.8) 572 (31.7)   348 (30.2) 247 (32.3) 101 (25.9)  
2006 1,537 (42.6) 720 (41.3) 817 (43.8)   1,480 (32.9) 857 (31.9) 623 (34.5)   394 (34.1) 263 (34.4) 131 (33.6)  
2007 520 (14.4) 223 (12.8) 297 (15.9)   1,140 (25.4) 687 (25.5) 453 (25.1)   315 (27.3) 194 (25.4) 121 (31.0)  
2008 121 (3.4) 46 (2.6) 75 (4.0)   315 (7.0) 157 (5.8) 158 (8.8)   97 (8.4) 60 (7.9) 37 (9.5)  
  1. P: P value; CCI: Charlson Comorbidity Index; 5-HT3 RAs: 5-hydroxytryptamine receptor antagonists.